Search research articles
Contact Us
Filters
Showing results (191-200 of 235) with videos related to
Page
of 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer
Jiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
Laura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer
Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, et al.
Nature
|
May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitness
David Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N Gettinger, Leora Horn, Leena Gandhi, et al.
Cancer Cell
|
January 12, 2024
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon, Adam J Schoenfeld, Darwin Ye, et al.
Cancer Cell
|
April 17, 2018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D Hellmann, Tavi Nathanson, Hira Rizvi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Cancer Cell
|
March 31, 2023
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
Joy A Pai, Matthew D Hellmann, Jennifer L Sauter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T R Cottrell, E D Thompson, P M Forde, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 235) with videos related to
Sort By:
Page
of 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 23, 2019
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer
Jiajia Zhang, Zhicheng Ji, Justina X Caushi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2021
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
Laura Mezquita, Isabel Preeshagul, Edouard Auclin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2024
Intratumoral Escherichia Is Associated With Improved Survival to Single-Agent Immune Checkpoint Inhibition in Patients With Advanced Non-Small-Cell Lung Cancer
Arielle Elkrief, Meagan Montesion, Smruthy Sivakumar, et al.
Nature
|
May 11, 2022
Fundamental immune-oncogenicity trade-offs define driver mutation fitness
David Hoyos, Roberta Zappasodi, Isabell Schulze, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 22, 2015
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N Gettinger, Leora Horn, Leena Gandhi, et al.
Cancer Cell
|
January 12, 2024
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Danish Memon, Adam J Schoenfeld, Darwin Ye, et al.
Cancer Cell
|
April 17, 2018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D Hellmann, Tavi Nathanson, Hira Rizvi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 6, 2021
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status
Biagio Ricciuti, Kathryn C Arbour, Jessica J Lin, et al.
Cancer Cell
|
March 31, 2023
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
Joy A Pai, Matthew D Hellmann, Jennifer L Sauter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2018
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T R Cottrell, E D Thompson, P M Forde, et al.
Page
of 24